Current treatment of cancer spread beyond the primary organ of origin (metastatic cancer) is based on combination of drugs that kill cancer cells and called Chemotherapy. It is important to understand that this group of medications contains numerous agents of different families with various mechanisms of action and different toxicity profiles.
 
The development of biological therapies and other targeted therapies based on the principal of selective binding of biological agents to cancer cells is a major leap forward in cancer therapy.
 
However, despite the major developments in cancer therapy, most patients with metastasis to the peritoneum will not be cured without surgery.
 
The option of cytoreductive surgery and HIPEC provides a new avenue to selected patients with peritoneal surface malignancies.